Panbela Therapeutics' core business segment revolves around the research, development, and clinical testing of novel oncology drugs, with a primary focus on pancreatic cancer. The company's lead product candidate, SBP-101, is currently undergoing Phase 1a/1b clinical trials for the treatment of metastatic pancreatic ductal adenocarcinoma. Research efforts are directed towards understanding the drug's mechanism of action, optimizing its formulation, and evaluating its efficacy in preclinical and clinical settings. The company employs various technologies and methodologies, including molecular biology, biochemistry, and clinical trial design, to advance its oncology drug development programs. The ultimate goal is to improve patient outcomes and address the unmet medical needs in cancer treatment. Future opportunities include expanding the pipeline with additional oncology drug candidates and exploring combination therapies to enhance treatment efficacy. Regulatory and clinical aspects are crucial, with ongoing efforts to obtain FDA approval for SBP-101 and other pipeline products.